Tradestie Institutional Equity Comparison Engine

ZBIO vs ALMS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while ALMS counters with relative strength in Growth & Margin. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus ALMS at N/M Forward P/E and -5938.1% operating margin (-7.7% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against ALMS sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ZBIO N/M vs ALMS N/M Fwd P/E
Growth & Margin Winner ALMS
Op Margin -2747.5% vs -5938.1% ยท YoY -100.0% vs -7.7%
Momentum & Technical Winner ZBIO
1Y -21.7% vs -2.6% ยท 52W Pos 46% vs 2%
Options & Structure Winner ZBIO
CONSOLIDATION (13th %ile IV) vs BREAKDOWN (6th %ile IV)
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
ALMS NASDAQ
Alumis Inc. Common Stock
Pharmaceutical Preparations
$5.14
-8.21% 1D
Market Cap $727.0M
1M Return -16.01%
1Y Return -2.65%
Forward P/E N/M
Unified AI Score
43.3 / 100 HOLD
Tech 20.0 Fund 51.0 Flow 67.0 Mom 74.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZBIO -21.68% ALMS -2.65% Spread: +19.03 pp (ALMS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ZBIO Revenue ALMS Revenue ZBIO Op. Margin ALMS Op. Margin Margin Edge
FY2023 $50M N/A -74.3% N/A ZBIO
FY2024 $10M N/A -3277.8% N/A ZBIO
FY2025 $10M $20M -3830.6% -1886.9% ALMS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZBIO (5) vs ALMS (2)
Institutional Metric ZBIO ALMS Criterion Row Winner
Market Capitalization Scale $1.9B $727.0M Larger Scale ZBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% -7.7% Higher Growth ALMS
Operating Margin (TTM) Profitability -2747.5% -5938.1% Higher Margin ZBIO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -265.1% -110.9% Higher ROE ALMS
52-Week Range Position Momentum 46% ($14โ€“$45) 2% ($5โ€“$31) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 59% Vol 2.24ฮฒ ยท 86% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZBIO vs ALMS Buy Guide
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ALMS BREAKDOWN
91d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ALMS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZBIO nor ALMS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.